The non-exclusive, multi-year license and supply agreement
enables use of LentiVector® with any Kyverna
product
Agreement supports Kyverna's scalability and reliability of
CAR T cell manufacturing goals
EMERYVILLE, Calif., Sept. 20,
2023 /PRNewswire/ -- Kyverna Therapeutics
("Kyverna"), a clinical-stage cell therapy company with the mission
of engineering a new class of therapies for serious autoimmune
diseases, today announced a non-exclusive, multi-year license and
supply agreement with Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica"), a quality and innovation-led viral vector Contract and
Development Manufacturing Organization (CDMO), enabling the
use of LentiVector® with any Kyverna product.
The LentiVector® platform is the first commercially approved
lentiviral-based gene delivery system. The platform enables the
successful development of breakthrough gene and cell-based
medicines.
Kyverna's anti-CD19 chimeric antigen receptor (CAR) T-cell
therapies, KYV-101 and KYV-201, specifically target CD19, a protein
expressed on the surface of B cells which are involved in various
types of autoimmune diseases, including lupus nephritis. These
novel therapies have the potential to offer new hope to patients
who have exhausted current treatment options. Kyverna's
KYV-101 CAR T-cell product is currently being tested in a Phase 1
clinical trial in lupus nephritis in the U.S. and a Phase 1/2 trial
in Germany.
"We are committed to quality and innovation. As a world-leading
CDMO with expertise across all key viral vector types, we are
committed to enabling our biopharma customers to discover and
deliver transformative therapies", said Dr. Sebastien Ribault, chief commercial officer of
Oxford Biomedica. "We are excited to work with Kyverna as an
innovative leader in cell therapy for autoimmune diseases and look
forward to a fruitful partnership."
"We are delighted to be working with Oxford Biomedica, a
recognized leader in reliable, quality vector supply. We value
Oxford Biomedica's extensive capabilities and technologies to
enable efficient and cost-effective manufacturing, which is
critical in the vast market of B cell-driven autoimmune diseases
that our therapies address," commented Karen Walker, chief technology officer at
Kyverna.
About Oxford Biomedica
Oxford Biomedica is a quality and innovation-led viral
vector CDMO with a mission to enable its clients to deliver
life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, Oxford
Biomedica has more than 25 years of experience in viral vectors;
the driving force behind the majority of gene therapies, and
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialization. These capabilities are supported
by robust quality-assurance systems, analytical methods, and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations
across Oxfordshire, UK and near
Boston, MA, US. Learn more
at www.oxb.com, www.oxbsolutions.com.
About KYV-101
KYV-101 is an autologous version of a novel, fully human
clinical-stage anti-CD19 chimeric antigen receptor (CAR) T-cell
construct with properties well suited for use in B cell-driven
autoimmune diseases such as lupus nephritis and other B-cell driven
autoimmune diseases. In a 20-patient Phase 1/2 study in oncology,
expected anti-lymphoma activity was associated with a significant
reduction of cytokines released that translated into a strong
reduction of cytokine-driven side effects such as the rate of
immune effector cell-associated neurotoxicity syndrome
(ICANS)1. The fully human anti-CD19 CAR also translated
into reduced immunogenicity that favorably impacted cell
persistence at one month. Kyverna recognized that these properties
singled out KYV-101 as a product ideally poised for use in
autoimmune disease patients, and the company obtained exclusive,
worldwide licenses from the National Institutes of Health (NIH) to
use this CD19 construct in both autologous and allogeneic CAR
T-cell therapies.
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage cell therapy
company with the mission of engineering a new class of therapies
for autoimmune and inflammatory diseases. The Kyverna therapeutic
platform combines advanced T-cell engineering and synthetic biology
technologies to suppress and eliminate the autoreactive immune
cells at the origin of autoimmune and inflammatory diseases.
Kyverna's pipeline includes next-generation chimeric antigen
receptor (CAR) T-cell therapies in both autologous and allogeneic
formats with properties well suited for use in B cell-driven
autoimmune diseases. By offering more than one mechanism for taming
autoimmunity, Kyverna is positioned to act on its mission of
transforming how autoimmune diseases are treated. For more
information, please visit https://kyvernatx.com.
Media Contact:
Kyverna:
Christian Pflaumer
+1 (917) 841-4525
christian.pflaumer@ruderfinn.com
References:
1Brudno et al., Nature Medicine 2020;
26:270-280.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-and-oxford-biomedica-sign-license-and-supply-agreement-for-lentivector-platform-301932842.html
SOURCE Kyverna Therapeutics